Latest Immunosuppressive agents Stories
This report provides perspective on the MS landscape in light of Merck Seronoâ€™s decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled â€œThought Leader Insight & Analysis: Multiple Sclerosis,â€ designed to provide critical strategic insight for pharma and biotech companies...
The drug laquinimod reduced the number of instances in relapses for individuals with multiple sclerosis (MS) in a long-term, phase III clinical study involving 1,106 participants with relapsing-remitting MS in 24 countries.
Patients with rheumatoid arthritis, a crippling disease that eats away at the joints and causes severe pain and swelling, arenâ€™t receiving their much-needed, low-cost drugs that prevent deformity.
SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.
A study conducted at Copenhagen University Hospital showed that treatment of rheumatoid arthritis (RA) with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents significantly reduced radiographic evidence of joint destruction, with a relative effect of 48%óˆž´% as compared with placebo.
Disease-modifying antirheumatic drugs (DMARDs) should be used early and aggressively at the first sign of rheumatoid arthritis (RA).
EAST HANOVER, N.J., June 10 /PRNewswire/ -- Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease.
NORTHBROOK, Ill., May 19 /PRNewswire/ -- Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and chronic inflammation, today announced interim results from a pilot clinical study showing that LODOTRAÂ® (modified release prednisone tablet) chronotherapy may improve asthma control and asthma-related quality of life when added to standard asthma therapy in patients with severe nocturnal...
JAMESBURG, N.J., Aug. 19 /PRNewswire/ -- Phytomedics Inc.
- Results of Phase III clinical studies highlight benefits of ACTEMRA as a treatment for rheumatoid arthritis - NUTLEY, N.J., June 4 /PRNewswire/ -- Roche today announced that oral and poster presentations highlighting results from the extensive multi-national ACTEMRA(R) (tocilizumab) clinical development program will be presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR), which will take place June 10-13, 2009, in Copenhagen, Denmark.
- An armed gangster.